{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-009136","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2023-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.832293+00:00","generated_at":"2026-06-07T05:52:45.323179+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Odyssey Health closes asset sale of brain illness drug candidates to Oragenics for $1M cash and 8M preferred shares","bullets":["Sold drug candidates for mild traumatic brain injury and Niemann Pick Disease Type C, plus proprietary powder formulation and nasal delivery device.","Received $1M in cash plus 8M shares of convertible Series F Preferred Stock from Oragenics.","Closing conditions included shareholder approvals from both Odyssey and Oragenics; no material adverse change required.","Odyssey previously disclosed the Purchase Agreement in an October 5, 2023 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-009136","json":"https://secwatch.observer/filing/0001683168-23-009136.json","markdown":"https://secwatch.observer/filing/0001683168-23-009136.md","text":"https://secwatch.observer/filing/0001683168-23-009136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/0001683168-23-009136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T05:52:45.323179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47ac1c775502e8a13a0508ee71f0f65574325ff5","claim":"Odyssey Health, Inc. completed a disposition involving Oragenics, Inc. for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (closed 2023-12-28).","evidence_excerpt":"to a segment of Odyssey’s business focused on developing medical products that treat brain related illnesses and diseases (the “ Purchased Assets ”) to Oragenics in exchange for $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (“ Series F Preferred Stock ”), on and subject to the terms and conditions set forth therein","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823009136/0001683168-23-009136-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Oragenics, Inc."},{"label":"Consideration","value":"$1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock"},{"label":"Closing","value":"2023-12-28"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}